Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort

Clinical Infectious Diseases

Volumn 49, Issue 6, 2009, Pages 965-972

  Castelnuovo, Barbara ^a,d   Manaba, Yukari C ^a,b   Kiragga, Agnes ^a   Kamya, Moses ^a   Easterbrook, Philippa ^c   Kambugu, Andrew ^a  

^a MAKERERE UNIVERSITY   (Uganda)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d MULAGO HOSPITAL   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; UNCLASSIFIED DRUG; ZIDOVUDINE PLUS LAMIVUDINE PLUS EFAVIRENZ;

ADULT; ARTICLE; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CRYPTOCOCCAL MENINGITIS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; TUBERCULOSIS; UGANDA; URBAN AREA;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; KAPLAN-MEIERS ESTIMATE; MALE; MENINGITIS, CRYPTOCOCCAL; PROPORTIONAL HAZARDS MODELS; TIME FACTORS; TUBERCULOSIS; UGANDA;

EID: 70049108486     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/605500     Document Type: Article

References (32)

1. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004; 18:887-895 (Pubitemid 38553709)
2. Ivers LC, Kendrick D, Doucette K. Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis 2005;41:217-224 (Pubitemid 40962502)
3. Wester CW, Kim S, Bussmann H, et al. Initial response to highly active antiretroviral therapy in HIV-1 C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defic Syndr 2005;40:336-343 (Pubitemid 41533075)
4. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 2005; 19:2109-2116 (Pubitemid 41668999)
5. Moh R, Danel C, Messou E, et al. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS 2007;21:2483-2491 (Pubitemid 350145180)
6. Braitstein P, BrinkhofMW, Dabis F, et al. Mortality of'HIV-1-inf'ected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006;367:817-824
7. Etard JF, Ndiaye I, Thierry-Mieg M, et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7year cohort study. AIDS 2006;20:1181-1189 (Pubitemid 43786107)
8. Zachariah R, Fitzgerald M, Massaquoi M, et al. Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS 2006;20:2355-2360 (Pubitemid 44789538)
9. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in subSaharan Africa. AIDS 2008;22:1897-1908
10. Dalai RP, Macphail C, Mqhayi M, et al. Characteristics and outcomes of adult patients lost to follow-up at an antiretroviral treatment clinic in Johannesburg, South Africa. J Acquir Immune Defic Syndr 2008; 47:101-107 (Pubitemid 351619376)
11. Muwanga A, Easterbrook P, Schaefer P, et al. Losses to follow-up in a large ART program in Uganda [abstract 840]. In: Program and abstracts of the 2008 Conference on Retroviruses and Oportunistic Infections (Boston, Massachusetts).
12. Yiannoutsos CT, An MW, Frangakis CE, et al. Sampling-based approaches to improve estimation of mortality among patient dropouts: experience from a large PEPFAR-funded program in Western Kenya. PLoS ONE 2008; 3:e3843.
13. Anglaret X, Toure S, Gourvellec G, et al. Impact of vital status investigation procedures on estimates of survival in cohorts of HIV-infected patients from sub-Saharan Africa. J Acquir Immune Defic Syndr 2004;35:320-323 (Pubitemid 38280660)
14. Bisson GP, Gaolathe T, Gross R, et al. Overestimates of survival after HAART: implications for global scale-up efforts. PLoS ONE 2008; 3: e1725. (Pubitemid 351903231)
15. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 2007;4: e298. (Pubitemid 350035458)
16. Lawn SD, Wilkinson RJ, Lipman MC, Wood R. Immune reconstitution and "unmasking" of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med 2008;177:680-685
17. Manabe YC, Breen RA, Perti T, Girardi E, Sterling TR. Unmasked tuberculosis and tuberculosis immune reconstitution inflammatory disease: a disease spectrum after highly active antiretroviral therapy initiation. J Infect Dis 2009; 199:437-444
18. Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998; 158:157-161 (Pubitemid 28337174)
19. Kamya MR, Mayanja-Kizza H, Kambugu A, et al. Predictors of longterm viral failure among Ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr 2007;46:187-193 (Pubitemid 47482614)
20. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008;8:516-523 (Pubitemid 352005824)
21. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 2004;18:1615-1627 (Pubitemid 39095778)
22. Weidle PJ, Malamba S, Mwebaze R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet 2002; 360:34-40. (Pubitemid 34756490)
23. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006;296:782-793 (Pubitemid 44223102)
24. Liechty CA, Solberg P, Were W, et al. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health 2007;12:929-935 (Pubitemid 47245826)
25. Jarvis JN, Lawn SD, Vogt N, Bangani R, Wood R, Harrison TS. Screening for cryptocccal antigenaemia in patients acessing an atiretroviral treatment proram in South Africa. Clin Infect Dis 2009;48:856-862
26. Murdoch DM, Venter WD, Feldman C, Van Rie A. HIV immune reconstitution syndrome in sub-Saharan Africa. AIDS 2008;22:1689-1690
27. Kambugu A, Meya DB, Rhein J, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis 2008;46:1694-1701 (Pubitemid 351706766)
28. Songa PM, Castelnuovo B, Mugasha EB, Ocama P, Kambugu A. Symptomatic hyperlactatemia associated with nucleoside analogue reversetranscriptase inhibitor use in HIV-infected patients: a report of 24 cases in a resource-limited setting (Uganda). Clin Infect Dis 2007;45:514-517 (Pubitemid 47204473)
29. Risk factors for lactic acidosis and severe hyperlactataemia in HIV- 1-infected adults exposed to antiretroviral therapy. AIDS 2007;21:2455-2464
30. Seyler C, Anglaret X, Dakoury-Dogbo N, et al. Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Cote d'Ivoire. Antivir Ther 2003;8: 385-393 (Pubitemid 37351556)
31. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 2005; 19:2141-2148 (Pubitemid 41669003)
32. Laurent C, Ngom Gueye NF, Ndour CT, et al. Long-term benefits of highly active antiretroviral therapy in Senegalese HIV- 1-infected adults. J Acquir Immune Defic Syndr 2005;38:14-17 (Pubitemid 40094112)